SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture
TEL AVIV, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, that CliniQuantum Ltd. (“CliniQuantum”), NeuroThera’s majority owned subsidiary, reported that its Graphics Processing Unit- accelerated (“GPU”) quantum-simulation platform achieved an approximately 16.8-fold computational acceleration using a single machine with 64 cores (x86_64) and a single NVIDIA T4 Tensor Core GPU compared with the same 64-vCPU machine with only Central Processing Unit (“CPU”) implementation.
Covered in this story
What has happened since
- TE Connectivity is down 2.0% since this was published, 13 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on TE Connectivity
- Bernstein: $214 → $243 by Sep 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $TEL yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on TE Connectivity →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.